4//SEC Filing
Kumar Rakhi 4
Accession 0001140361-25-005053
CIK 0001635088other
Filed
Feb 17, 7:00 PM ET
Accepted
Feb 18, 9:00 PM ET
Size
8.6 KB
Accession
0001140361-25-005053
Insider Transaction Report
Form 4
Kumar Rakhi
Chief Accounting Officer
Transactions
- Exercise/Conversion
Common Shares
2025-02-13$3.85/sh+187,500$721,875→ 390,764 total - Sale
Common Shares
2025-02-13$10.43/sh−227,500$2,372,825→ 163,264 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-02-13−187,500→ 312,500 totalExercise: $3.85Exp: 2032-04-19→ Common Stock (187,500 underlying)
Footnotes (2)
- [F1]The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
- [F2]Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).
Documents
Issuer
Roivant Sciences Ltd.
CIK 0001635088
Entity typeother
Related Parties
1- filerCIK 0001856296
Filing Metadata
- Form type
- 4
- Filed
- Feb 17, 7:00 PM ET
- Accepted
- Feb 18, 9:00 PM ET
- Size
- 8.6 KB